Is Good News Enough for You to Buy NGM on the Dip?
If revenue is not yet being generated from products, a company's stock price can rely heavily on positive news from treatment candidates moving through clinical trials. NGM Biopharmaceuticals (NASDAQ: NGM) has had a few ups and downs in its clinical trials in 2021, leading to fluctuations in stock price. Does NGM have what it takes to go the distance?